DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has launched the VELYS Active Robotic-Assisted System (VELYS SPINE), a new dual-use robotics and standalone navigation platform.
Developed by DePuy Synthes in collaboration with eCential Robotics, the system has received 510(k) clearance from the US Food and Drug Administration (FDA) and is designed for use in spinal fusion procedures in the thoracolumbar, cervical and sacroiliac spine.
The VELYS SPINE system is poised to establish a new standard in spine surgical care with its active robotics technology, which provides surgical guidance tailored to surgeon preferences.
This technology is intended to assist surgeons in addressing complex challenges by offering a customisable experience with pathology-specific workflows, VELYS adaptive tracking technology, and VELYS trajectory assistance.
DePuy Synthes company group chair Aldo Denti said: “We are shaping the next frontier of orthopaedic innovation with a relentless focus on digital advancements and excellence in the field of surgical robotics and navigation.
“This is a major step in growing our VELYS portfolio and in our commitment to supporting spine surgeons and their patients with advanced tools.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe system is designed for use with DePuy Synthes’ core spine portfolio, including the SYMPHONY occipito-cervico-thoracic (OCT) system, TriALTIS spine system and navigation-enabled instruments, VIPER PRIME system, and EXPEDIUM VERSE systems.
Its features are expected to enhance the flexibility and precision of spinal surgeries.
The system’s commercial availability is anticipated in the first half of 2025.
DePuy Synthes Spine worldwide president Russell Powers said: “Today’s landscape of enabling technologies features first-generation robotics systems that may face challenges in adapting to individual surgeon needs.
“We believe that the unique features and capabilities of active robotics technology will set a new standard in surgical care for spine patients everywhere.”
In June 2024, DePuy Synthes obtained 510(k) clearance for the clinical application of its Velys robotic-assisted system for unicompartmental knee arthroplasty procedures.